Enlivex Therapeutics Stock (NASDAQ:ENLV)
Previous Close
$1.05
52W Range
$0.99 - $4.59
50D Avg
$1.44
200D Avg
$1.89
Market Cap
$22.05M
Avg Vol (3M)
$131.04K
Beta
1.10
Div Yield
-
ENLV Company Profile
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
ENLV Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MRUS | Merus N.V. |
| CRVS | Corvus Pharmaceuticals, Inc. |
| VCEL | Vericel Corporation |
| PPBT | Purple Biotech Ltd. |
| BLRX | BioLineRx Ltd. |
| APVO | Aptevo Therapeutics Inc. |
| ALDX | Aldeyra Therapeutics, Inc. |
| CKPT | Checkpoint Therapeutics, Inc. |
| CLGN | CollPlant Biotechnologies Ltd. |
| ARDS | Aridis Pharmaceuticals, Inc. |
| GMDA | Gamida Cell Ltd. |
| PHIO | Phio Pharmaceuticals Corp. |
| KROS | Keros Therapeutics, Inc. |